Earlier, GeoVax Labs announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, "Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein." "Our novel Zika vaccine candidate, GEO-ZM02, is constructed using our modified vaccinia Ankara vector platform. Preclinical studies demonstrated a single dose of GEO-ZM02 provided 100% protection against a lethal dose of Zika virus," stated GeoVax CEO David Dodd. "Addressing many of the world’s most threatening infectious diseases is part of our vision and corporate priorities for MVA’s applications, which also includes an MVA-based next-generation COVID-19 vaccine currently in Phase 2 clinical trials."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GOVX:
- GeoVax to Present at the 2023 BIO CEO & Investor Conference
- GeoVax Receives Notice of Allowance for Zika Vaccine Patent
- GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
- GeoVax Labs appoints Rice President, CEO of Morehouse School of Medicine
- Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax